Advertisement
Canada markets closed
  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • DOW

    37,775.38
    +22.07 (+0.06%)
     
  • CAD/USD

    0.7245
    -0.0018 (-0.25%)
     
  • CRUDE OIL

    85.68
    +2.95 (+3.57%)
     
  • Bitcoin CAD

    83,203.14
    -1,676.34 (-1.97%)
     
  • CMC Crypto 200

    1,255.94
    +370.40 (+39.36%)
     
  • GOLD FUTURES

    2,426.40
    +28.40 (+1.18%)
     
  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     
  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     
  • NASDAQ futures

    17,213.25
    -334.00 (-1.90%)
     
  • VOLATILITY

    18.00
    -0.21 (-1.15%)
     
  • FTSE

    7,877.05
    +29.06 (+0.37%)
     
  • NIKKEI 225

    36,875.74
    -1,203.96 (-3.16%)
     
  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Stocks - Caesars Entertainment, Deere Rise Premarket; Spotify, Bristol-Myers Falls

Investing.com - Stocks in focus in premarket trading on Monday:

• Caesars Entertainment (NASDAQ:CZR) stock jumped 13% by 8:20 AM ET (12:20 GMT) after casino operator Eldorado Resorts (NASDAQ:ERI) agreed to merge with it in a cash and stock deal that valued Caesars at about $17.3 billion including debt. The combined deal will create a huge competitor to other casino players, including Wynn Resorts (NASDAQ:WYNN) and MGM Resorts (NYSE:MGM).

• Bristol-Myers Squibb (NYSE:BMY) stock fell 4% as it said it would divest Celgene’s arthritis med Otezla in an aim to get the sign off from the U.S. Federal Trade Commission on its planned takeover of Celgene (NASDAQ:CELG), which was down 3.7%. Otezla accounts for around 10% of Celegen’s sales.

• Deere & Company (NYSE:DE) stock gained 1.1% after Jefferies upgraded the tractor maker to “buy” from “hold”, according to CNBC.

ADVERTISEMENT

• Spotify (NYSE:SPOT) stock fell 3.5% after Evercore ISI downgraded it to “underperform” from “in line,” saying it doesn’t see the company generating enough profit over the medium-term, CNBC reported.

• Palatin (NYSE:PTN) stock surged 28.6%, while AMAG Pharmaceuticals (NASDAQ:AMAG) rose 8.5% after the U.S. Federal Drug Administration approved its Vyleesi treatment for low libido in women.

Related Articles

Danske Bank ousts former interim CEO after customers overcharged

Rivals ride rising rates as Lloyd's abandons some ship insurance

Futures edge higher with trade talks in focus